Michael A. Robinson
Michael'S LATEST HEADLINES
-
The Incredible Technology Saving Critically Ill COVID-19 Patients
One of the starkest lessons of the global novel coronavirus pandemic is the need for medicine to start looking at existing drugs and procedures in a new way.
We've already seen the benefits of such an approach. The discovery that remdesivir and dexamethasone – an antiviral and a steroid – could both help save severely ill COVID-19 patients' lives springs right to mind.
But adapting the old to fight the new isn't just limited to drugs. Existing medical technology ("medtech") is being used in entirely new ways, or in situations that would've been unthinkable just 10 or 12 months ago.
That's why today I want to talk to you about two compelling companies behind a radical, aggressive therapy that can deliver a "one-two punch" for coronavirus patients who might've otherwise died… Full Story
That's why today I want to talk to you about two compelling companies behind a radical, aggressive therapy that can deliver a "one-two punch" for coronavirus patients who might've otherwise died... - How You Can Profit from the Next Transistor Revolution
- Why Your Next Big Profit Opportunity Is Companies Getting Smaller
- Buy This "Post-COVID America" Money-Doubler at a Great Discount
- Forget the “Cashless Future” – the Cashless Now Is Where the Profit Is
- Make This High-Profit Nuclear Play (Before the Market Realizes It's Actually "Green")
- A Federal “Hack-Proof Web” Project Will Make This Money-Doubling Tech Stock Even Better
- Biotech (and Its IPOs) Will Crush Records in 2020 - Here's How to Profit
- Why This Defense Sector Play Is a Buy Now
- One of the Biggest Mergers in Defense History Created This "Must Buy" Security Play